Review



igf2  (Biosynth Carbosynth)


Bioz Verified Symbol Biosynth Carbosynth is a verified supplier
Bioz Manufacturer Symbol Biosynth Carbosynth manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Biosynth Carbosynth igf2
    Igf2, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/igf2/product/Biosynth Carbosynth
    Average 93 stars, based on 1 article reviews
    igf2 - by Bioz Stars, 2026-05
    93/100 stars

    Images



    Similar Products

    93
    Thermo Fisher gene exp ins igf2 hs01005963 m1
    Gene Exp Ins Igf2 Hs01005963 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gene exp ins igf2 hs01005963 m1/product/Thermo Fisher
    Average 93 stars, based on 1 article reviews
    gene exp ins igf2 hs01005963 m1 - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    93
    R&D Systems igf2
    Igf2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/igf2/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    igf2 - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    93
    R&D Systems igf 2
    PTN regulates endometrial stromal cell decidualization through <t>the</t> <t>IGF-2</t> signaling axis. (A) PPI network of PTN, IGF-2, IGFBP1, LIF, PRL, and other decidualization-related genes. (B) The expression levels of PTN and its interacting partners (IGF-2, WNT4, PRL, IGFBP1, and LIF) in the RIF (left) and RPL (right) datasets. (C) Expressions of decidualization-related genes (including IGFBP1 , LIF , PRL , and WNT4 ) in NC or si PTN hESCs after treatment with control vehicle, cAMP, and IGF-2 via RT-qPCR (n = 9). (D) Immunoblotting for PTN, IGFBP1, and PRL expression levels with control vehicle, cAMP, and IGF-2. (E) ELISA for IGF-2 levels with control vehicle, cAMP, and IGF-2. (F) Schematic diagram of the experiments performed using the different treatments of hESCs. Data are presented as mean ± SEM and analyzed using t-test or one-way ANOVA test. * compared with NC treated with control vehicle, # compared with si PTN treated with control vehicle, $ compared with si PTN treated with control cAMP (NS, no significant difference; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ####p < 0.0001, $p < 0.05, $$p < 0.01, $$$p < 0.001, $$$$p< 0.0001). PPI, protein–protein interaction; RIF, recurrent implantation failure; RPL, recurrent pregnancy loss; hESCs, human endometrial stromal cells; cAMP, cyclic adenosine monophosphate.
    Igf 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/igf 2/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    igf 2 - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    94
    R&D Systems recombinant mouse igf ii
    PTN regulates endometrial stromal cell decidualization through <t>the</t> <t>IGF-2</t> signaling axis. (A) PPI network of PTN, IGF-2, IGFBP1, LIF, PRL, and other decidualization-related genes. (B) The expression levels of PTN and its interacting partners (IGF-2, WNT4, PRL, IGFBP1, and LIF) in the RIF (left) and RPL (right) datasets. (C) Expressions of decidualization-related genes (including IGFBP1 , LIF , PRL , and WNT4 ) in NC or si PTN hESCs after treatment with control vehicle, cAMP, and IGF-2 via RT-qPCR (n = 9). (D) Immunoblotting for PTN, IGFBP1, and PRL expression levels with control vehicle, cAMP, and IGF-2. (E) ELISA for IGF-2 levels with control vehicle, cAMP, and IGF-2. (F) Schematic diagram of the experiments performed using the different treatments of hESCs. Data are presented as mean ± SEM and analyzed using t-test or one-way ANOVA test. * compared with NC treated with control vehicle, # compared with si PTN treated with control vehicle, $ compared with si PTN treated with control cAMP (NS, no significant difference; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ####p < 0.0001, $p < 0.05, $$p < 0.01, $$$p < 0.001, $$$$p< 0.0001). PPI, protein–protein interaction; RIF, recurrent implantation failure; RPL, recurrent pregnancy loss; hESCs, human endometrial stromal cells; cAMP, cyclic adenosine monophosphate.
    Recombinant Mouse Igf Ii, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant mouse igf ii/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    recombinant mouse igf ii - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    96
    Proteintech anti igf2 bp3 rabbit pab
    PTN regulates endometrial stromal cell decidualization through <t>the</t> <t>IGF-2</t> signaling axis. (A) PPI network of PTN, IGF-2, IGFBP1, LIF, PRL, and other decidualization-related genes. (B) The expression levels of PTN and its interacting partners (IGF-2, WNT4, PRL, IGFBP1, and LIF) in the RIF (left) and RPL (right) datasets. (C) Expressions of decidualization-related genes (including IGFBP1 , LIF , PRL , and WNT4 ) in NC or si PTN hESCs after treatment with control vehicle, cAMP, and IGF-2 via RT-qPCR (n = 9). (D) Immunoblotting for PTN, IGFBP1, and PRL expression levels with control vehicle, cAMP, and IGF-2. (E) ELISA for IGF-2 levels with control vehicle, cAMP, and IGF-2. (F) Schematic diagram of the experiments performed using the different treatments of hESCs. Data are presented as mean ± SEM and analyzed using t-test or one-way ANOVA test. * compared with NC treated with control vehicle, # compared with si PTN treated with control vehicle, $ compared with si PTN treated with control cAMP (NS, no significant difference; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ####p < 0.0001, $p < 0.05, $$p < 0.01, $$$p < 0.001, $$$$p< 0.0001). PPI, protein–protein interaction; RIF, recurrent implantation failure; RPL, recurrent pregnancy loss; hESCs, human endometrial stromal cells; cAMP, cyclic adenosine monophosphate.
    Anti Igf2 Bp3 Rabbit Pab, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti igf2 bp3 rabbit pab/product/Proteintech
    Average 96 stars, based on 1 article reviews
    anti igf2 bp3 rabbit pab - by Bioz Stars, 2026-05
    96/100 stars
      Buy from Supplier

    94
    Boster Bio primary antibodies against α sma
    PTN regulates endometrial stromal cell decidualization through <t>the</t> <t>IGF-2</t> signaling axis. (A) PPI network of PTN, IGF-2, IGFBP1, LIF, PRL, and other decidualization-related genes. (B) The expression levels of PTN and its interacting partners (IGF-2, WNT4, PRL, IGFBP1, and LIF) in the RIF (left) and RPL (right) datasets. (C) Expressions of decidualization-related genes (including IGFBP1 , LIF , PRL , and WNT4 ) in NC or si PTN hESCs after treatment with control vehicle, cAMP, and IGF-2 via RT-qPCR (n = 9). (D) Immunoblotting for PTN, IGFBP1, and PRL expression levels with control vehicle, cAMP, and IGF-2. (E) ELISA for IGF-2 levels with control vehicle, cAMP, and IGF-2. (F) Schematic diagram of the experiments performed using the different treatments of hESCs. Data are presented as mean ± SEM and analyzed using t-test or one-way ANOVA test. * compared with NC treated with control vehicle, # compared with si PTN treated with control vehicle, $ compared with si PTN treated with control cAMP (NS, no significant difference; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ####p < 0.0001, $p < 0.05, $$p < 0.01, $$$p < 0.001, $$$$p< 0.0001). PPI, protein–protein interaction; RIF, recurrent implantation failure; RPL, recurrent pregnancy loss; hESCs, human endometrial stromal cells; cAMP, cyclic adenosine monophosphate.
    Primary Antibodies Against α Sma, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against α sma/product/Boster Bio
    Average 94 stars, based on 1 article reviews
    primary antibodies against α sma - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    93
    Santa Cruz Biotechnology insulin like growth factor ii igf2
    Characterization of pluripotent stem cell markers in iPSCs. (A) Immunofluorescence staining showing qualitative expression of pluripotency markers SOX2 and TRA-1-60 in iPSC cell lines N7, N9, N11, and N12. Scale bar=200 μm. (B) qRT-PCR analysis of gene expression levels of pluripotency markers NANOG and OCT4 in the iPSC cell lines. Data are presented as mean±SEM from 3 independent experiments (n=3). (C) Immunofluorescence staining showing qualitative expression of the hematopoietic commitment marker <t>IGF2</t> in the iPSC cell lines. Scale bar=200 μm. (D) qRT-PCR analysis of gene expression levels of the hematopoietic commitment marker IGF2 and its receptor IGF1R in the iPSC cell lines. Data are presented as mean±SEM from 3 independent experiments (n=3). iPSCs: induced pluripotent stem cells, IGF2: insulin-like growth factor II.
    Insulin Like Growth Factor Ii Igf2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/insulin like growth factor ii igf2/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    insulin like growth factor ii igf2 - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    93
    Biosynth Carbosynth igf2
    Characterization of pluripotent stem cell markers in iPSCs. (A) Immunofluorescence staining showing qualitative expression of pluripotency markers SOX2 and TRA-1-60 in iPSC cell lines N7, N9, N11, and N12. Scale bar=200 μm. (B) qRT-PCR analysis of gene expression levels of pluripotency markers NANOG and OCT4 in the iPSC cell lines. Data are presented as mean±SEM from 3 independent experiments (n=3). (C) Immunofluorescence staining showing qualitative expression of the hematopoietic commitment marker <t>IGF2</t> in the iPSC cell lines. Scale bar=200 μm. (D) qRT-PCR analysis of gene expression levels of the hematopoietic commitment marker IGF2 and its receptor IGF1R in the iPSC cell lines. Data are presented as mean±SEM from 3 independent experiments (n=3). iPSCs: induced pluripotent stem cells, IGF2: insulin-like growth factor II.
    Igf2, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/igf2/product/Biosynth Carbosynth
    Average 93 stars, based on 1 article reviews
    igf2 - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    93
    R&D Systems ultrasensitive mouse insulin elisa kits
    Characterization of pluripotent stem cell markers in iPSCs. (A) Immunofluorescence staining showing qualitative expression of pluripotency markers SOX2 and TRA-1-60 in iPSC cell lines N7, N9, N11, and N12. Scale bar=200 μm. (B) qRT-PCR analysis of gene expression levels of pluripotency markers NANOG and OCT4 in the iPSC cell lines. Data are presented as mean±SEM from 3 independent experiments (n=3). (C) Immunofluorescence staining showing qualitative expression of the hematopoietic commitment marker <t>IGF2</t> in the iPSC cell lines. Scale bar=200 μm. (D) qRT-PCR analysis of gene expression levels of the hematopoietic commitment marker IGF2 and its receptor IGF1R in the iPSC cell lines. Data are presented as mean±SEM from 3 independent experiments (n=3). iPSCs: induced pluripotent stem cells, IGF2: insulin-like growth factor II.
    Ultrasensitive Mouse Insulin Elisa Kits, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ultrasensitive mouse insulin elisa kits/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    ultrasensitive mouse insulin elisa kits - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    93
    R&D Systems m r p caligf ii qkit
    Characterization of pluripotent stem cell markers in iPSCs. (A) Immunofluorescence staining showing qualitative expression of pluripotency markers SOX2 and TRA-1-60 in iPSC cell lines N7, N9, N11, and N12. Scale bar=200 μm. (B) qRT-PCR analysis of gene expression levels of pluripotency markers NANOG and OCT4 in the iPSC cell lines. Data are presented as mean±SEM from 3 independent experiments (n=3). (C) Immunofluorescence staining showing qualitative expression of the hematopoietic commitment marker <t>IGF2</t> in the iPSC cell lines. Scale bar=200 μm. (D) qRT-PCR analysis of gene expression levels of the hematopoietic commitment marker IGF2 and its receptor IGF1R in the iPSC cell lines. Data are presented as mean±SEM from 3 independent experiments (n=3). iPSCs: induced pluripotent stem cells, IGF2: insulin-like growth factor II.
    M R P Caligf Ii Qkit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/m r p caligf ii qkit/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    m r p caligf ii qkit - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    Image Search Results


    PTN regulates endometrial stromal cell decidualization through the IGF-2 signaling axis. (A) PPI network of PTN, IGF-2, IGFBP1, LIF, PRL, and other decidualization-related genes. (B) The expression levels of PTN and its interacting partners (IGF-2, WNT4, PRL, IGFBP1, and LIF) in the RIF (left) and RPL (right) datasets. (C) Expressions of decidualization-related genes (including IGFBP1 , LIF , PRL , and WNT4 ) in NC or si PTN hESCs after treatment with control vehicle, cAMP, and IGF-2 via RT-qPCR (n = 9). (D) Immunoblotting for PTN, IGFBP1, and PRL expression levels with control vehicle, cAMP, and IGF-2. (E) ELISA for IGF-2 levels with control vehicle, cAMP, and IGF-2. (F) Schematic diagram of the experiments performed using the different treatments of hESCs. Data are presented as mean ± SEM and analyzed using t-test or one-way ANOVA test. * compared with NC treated with control vehicle, # compared with si PTN treated with control vehicle, $ compared with si PTN treated with control cAMP (NS, no significant difference; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ####p < 0.0001, $p < 0.05, $$p < 0.01, $$$p < 0.001, $$$$p< 0.0001). PPI, protein–protein interaction; RIF, recurrent implantation failure; RPL, recurrent pregnancy loss; hESCs, human endometrial stromal cells; cAMP, cyclic adenosine monophosphate.

    Journal: Frontiers in Immunology

    Article Title: PTN/IGF-2 signaling modulates endometrial decidualization and immune cell trafficking to facilitate pregnancy maintenance

    doi: 10.3389/fimmu.2026.1790942

    Figure Lengend Snippet: PTN regulates endometrial stromal cell decidualization through the IGF-2 signaling axis. (A) PPI network of PTN, IGF-2, IGFBP1, LIF, PRL, and other decidualization-related genes. (B) The expression levels of PTN and its interacting partners (IGF-2, WNT4, PRL, IGFBP1, and LIF) in the RIF (left) and RPL (right) datasets. (C) Expressions of decidualization-related genes (including IGFBP1 , LIF , PRL , and WNT4 ) in NC or si PTN hESCs after treatment with control vehicle, cAMP, and IGF-2 via RT-qPCR (n = 9). (D) Immunoblotting for PTN, IGFBP1, and PRL expression levels with control vehicle, cAMP, and IGF-2. (E) ELISA for IGF-2 levels with control vehicle, cAMP, and IGF-2. (F) Schematic diagram of the experiments performed using the different treatments of hESCs. Data are presented as mean ± SEM and analyzed using t-test or one-way ANOVA test. * compared with NC treated with control vehicle, # compared with si PTN treated with control vehicle, $ compared with si PTN treated with control cAMP (NS, no significant difference; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ####p < 0.0001, $p < 0.05, $$p < 0.01, $$$p < 0.001, $$$$p< 0.0001). PPI, protein–protein interaction; RIF, recurrent implantation failure; RPL, recurrent pregnancy loss; hESCs, human endometrial stromal cells; cAMP, cyclic adenosine monophosphate.

    Article Snippet: The remaining cells were digested with trypsin and inoculated into a new culture dish, and they were treated with control vehicle or IGF-2 (50 ng/mL, R&D Systems, Minneapolis, MN, USA, 292-G2) for 48 h and then collected for quantitative real-time polymerase chain reaction (qRT-PCR).

    Techniques: Expressing, Control, Quantitative RT-PCR, Western Blot, Enzyme-linked Immunosorbent Assay

    IGF-2 promotes decidualization and rescues decidualization defects caused by PTN deficiency. (A) Schematic diagram of the experiments performed using the different treatments of ESCs isolated from endometrium of RIF and RPL patients. (B, C) RT-qPCR analysis of levels of decidualization-related genes in ESCs isolated from endometrium of RIF (B) and RPL (C) patients after IGF-2 (50 ng/mL) treatment for 48 h (n = 9). (D) The flowchart depicts the steps involved in establishing a mouse model of intrauterine perfusion with siRNA-mediated knockdown of PTN and then supplemented with IGF-2 (50 ng/mL) through tail vein injection. (E) Expression of PTN after Ptn knockdown and supplemented with control vehicle or IGF-2 (50 ng/mL) in the mouse endometrium, measured by immunofluorescence, and quantitative analysis of immunofluorescence was performed (n = 6). (F) RT-qPCR analysis of levels of decidualization-related genes after Ptn knockdown and supplemented with control vehicle or IGF-2 (50 ng/mL) in the mouse endometrium (n = 6). Data are presented as mean ± SEM and analyzed using t-test or one-way ANOVA test. * compared with NC treated with control vehicle, # compared with si PTN treated with control vehicle (NS, no significant difference; *p < 0.05, **p < 0.01, ***p < 0.001, ****p< 0.0001, ## p < 0.01, ### p < 0.001, #### p < 0.0001). ESCs, endometrial stromal cells; PPI, protein–protein interaction; RIF, recurrent implantation failure.

    Journal: Frontiers in Immunology

    Article Title: PTN/IGF-2 signaling modulates endometrial decidualization and immune cell trafficking to facilitate pregnancy maintenance

    doi: 10.3389/fimmu.2026.1790942

    Figure Lengend Snippet: IGF-2 promotes decidualization and rescues decidualization defects caused by PTN deficiency. (A) Schematic diagram of the experiments performed using the different treatments of ESCs isolated from endometrium of RIF and RPL patients. (B, C) RT-qPCR analysis of levels of decidualization-related genes in ESCs isolated from endometrium of RIF (B) and RPL (C) patients after IGF-2 (50 ng/mL) treatment for 48 h (n = 9). (D) The flowchart depicts the steps involved in establishing a mouse model of intrauterine perfusion with siRNA-mediated knockdown of PTN and then supplemented with IGF-2 (50 ng/mL) through tail vein injection. (E) Expression of PTN after Ptn knockdown and supplemented with control vehicle or IGF-2 (50 ng/mL) in the mouse endometrium, measured by immunofluorescence, and quantitative analysis of immunofluorescence was performed (n = 6). (F) RT-qPCR analysis of levels of decidualization-related genes after Ptn knockdown and supplemented with control vehicle or IGF-2 (50 ng/mL) in the mouse endometrium (n = 6). Data are presented as mean ± SEM and analyzed using t-test or one-way ANOVA test. * compared with NC treated with control vehicle, # compared with si PTN treated with control vehicle (NS, no significant difference; *p < 0.05, **p < 0.01, ***p < 0.001, ****p< 0.0001, ## p < 0.01, ### p < 0.001, #### p < 0.0001). ESCs, endometrial stromal cells; PPI, protein–protein interaction; RIF, recurrent implantation failure.

    Article Snippet: The remaining cells were digested with trypsin and inoculated into a new culture dish, and they were treated with control vehicle or IGF-2 (50 ng/mL, R&D Systems, Minneapolis, MN, USA, 292-G2) for 48 h and then collected for quantitative real-time polymerase chain reaction (qRT-PCR).

    Techniques: Isolation, Quantitative RT-PCR, Knockdown, Injection, Expressing, Control, Immunofluorescence

    PTN deficiency induces endometrial immune imbalance and leads to adverse pregnancy outcomes, which can be partially reversed by IGF-2. (A) PPI network of PTN, IGF-2, CXCR4, CD4, CD8, CD56, and other immunoregulators. (B, C) Flow cytometry analysis (B) and statistical quantification (C) of cell populations of NK cells and T cells, and the expression levels of CD16, CXCR4, and GZMB in NK cell form the endometrial tissues of NC and si PTN mice treated with control vehicle or IGF-2 (50 ng/mL) (n = 6). (D) The flowchart depicts the steps involved in establishing a mouse model of intrauterine perfusion with siRNA-mediated knockdown of Ptn and then supplemented with IGF-2 (50 ng/mL) through tail vein injection for 2 days; then, these female mice were mated with fertile male mice; analysis of fertility, including pregnancy rate, IF, and fluorescence-activated cell sorting (FACS). were performed at gestational day 13.5. (E) Representative images of uteri from pregnant mice in the NC and si PTN mice treated with control vehicle or IGF-2 (50 ng/mL) at gestational day 13.5 (n = 6) (arrow shows the absorption site). (F) Pregnancy rate (%) in NC and si PTN mice treated with control vehicle or IGF-2 (50 ng/mL) (n = 15). (G) Quantification of embryo numbers (left) and absorption rate (right) per mouse in NC (n = 13) and si PTN mice treated with control vehicle (n = 6) or IGF-2 (50 ng/mL) (n = 11) at gestational day 13.5. Data are presented as mean ± SEM and analyzed using one-way ANOVA test or χ 2 test. * Compared with NC treated with control vehicle, # compared with si PTN treated with control vehicle (NS, no significant difference; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ## p < 0.01, ### p < 0.001, #### p < 0.0001). IF, immunofluorescence.

    Journal: Frontiers in Immunology

    Article Title: PTN/IGF-2 signaling modulates endometrial decidualization and immune cell trafficking to facilitate pregnancy maintenance

    doi: 10.3389/fimmu.2026.1790942

    Figure Lengend Snippet: PTN deficiency induces endometrial immune imbalance and leads to adverse pregnancy outcomes, which can be partially reversed by IGF-2. (A) PPI network of PTN, IGF-2, CXCR4, CD4, CD8, CD56, and other immunoregulators. (B, C) Flow cytometry analysis (B) and statistical quantification (C) of cell populations of NK cells and T cells, and the expression levels of CD16, CXCR4, and GZMB in NK cell form the endometrial tissues of NC and si PTN mice treated with control vehicle or IGF-2 (50 ng/mL) (n = 6). (D) The flowchart depicts the steps involved in establishing a mouse model of intrauterine perfusion with siRNA-mediated knockdown of Ptn and then supplemented with IGF-2 (50 ng/mL) through tail vein injection for 2 days; then, these female mice were mated with fertile male mice; analysis of fertility, including pregnancy rate, IF, and fluorescence-activated cell sorting (FACS). were performed at gestational day 13.5. (E) Representative images of uteri from pregnant mice in the NC and si PTN mice treated with control vehicle or IGF-2 (50 ng/mL) at gestational day 13.5 (n = 6) (arrow shows the absorption site). (F) Pregnancy rate (%) in NC and si PTN mice treated with control vehicle or IGF-2 (50 ng/mL) (n = 15). (G) Quantification of embryo numbers (left) and absorption rate (right) per mouse in NC (n = 13) and si PTN mice treated with control vehicle (n = 6) or IGF-2 (50 ng/mL) (n = 11) at gestational day 13.5. Data are presented as mean ± SEM and analyzed using one-way ANOVA test or χ 2 test. * Compared with NC treated with control vehicle, # compared with si PTN treated with control vehicle (NS, no significant difference; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ## p < 0.01, ### p < 0.001, #### p < 0.0001). IF, immunofluorescence.

    Article Snippet: The remaining cells were digested with trypsin and inoculated into a new culture dish, and they were treated with control vehicle or IGF-2 (50 ng/mL, R&D Systems, Minneapolis, MN, USA, 292-G2) for 48 h and then collected for quantitative real-time polymerase chain reaction (qRT-PCR).

    Techniques: Flow Cytometry, Expressing, Control, Knockdown, Injection, Fluorescence, FACS, Immunofluorescence

    Characterization of pluripotent stem cell markers in iPSCs. (A) Immunofluorescence staining showing qualitative expression of pluripotency markers SOX2 and TRA-1-60 in iPSC cell lines N7, N9, N11, and N12. Scale bar=200 μm. (B) qRT-PCR analysis of gene expression levels of pluripotency markers NANOG and OCT4 in the iPSC cell lines. Data are presented as mean±SEM from 3 independent experiments (n=3). (C) Immunofluorescence staining showing qualitative expression of the hematopoietic commitment marker IGF2 in the iPSC cell lines. Scale bar=200 μm. (D) qRT-PCR analysis of gene expression levels of the hematopoietic commitment marker IGF2 and its receptor IGF1R in the iPSC cell lines. Data are presented as mean±SEM from 3 independent experiments (n=3). iPSCs: induced pluripotent stem cells, IGF2: insulin-like growth factor II.

    Journal: International Journal of Stem Cells

    Article Title: Induced Pluripotent Stem Cells Derived CD71 + CD235a + Erythroblasts Were Increased by Sirtuin 1 Activator

    doi: 10.15283/ijsc25040

    Figure Lengend Snippet: Characterization of pluripotent stem cell markers in iPSCs. (A) Immunofluorescence staining showing qualitative expression of pluripotency markers SOX2 and TRA-1-60 in iPSC cell lines N7, N9, N11, and N12. Scale bar=200 μm. (B) qRT-PCR analysis of gene expression levels of pluripotency markers NANOG and OCT4 in the iPSC cell lines. Data are presented as mean±SEM from 3 independent experiments (n=3). (C) Immunofluorescence staining showing qualitative expression of the hematopoietic commitment marker IGF2 in the iPSC cell lines. Scale bar=200 μm. (D) qRT-PCR analysis of gene expression levels of the hematopoietic commitment marker IGF2 and its receptor IGF1R in the iPSC cell lines. Data are presented as mean±SEM from 3 independent experiments (n=3). iPSCs: induced pluripotent stem cells, IGF2: insulin-like growth factor II.

    Article Snippet: The primary antibodies were rat anti-human SRY-box transcription factor 2 (SOX2) (Invitrogen, A24759), mouse anti-human tumor-related Antigen-1-60 (TRA-1-60) (Invitrogen, A24868), insulin-like growth factor II (IGF2) (Santa Cruz Biotechnology, sc-515805) and rabbit anti-human Runt-related transcription factor 1 (RUNX1) (Abcam, ab35962).

    Techniques: Immunofluorescence, Staining, Expressing, Quantitative RT-PCR, Gene Expression, Marker